Recombinant Rabbit monoclonal primary
DPYD Recombinant Rabbit Monoclonal Antibody [JE54-79] (ET7110-83)
Synthetic peptide corresponding to c-terminal human dpyd.
THP-1 cell lysates, SiHa cell lysates, human liver tissue.
Store at +4C after thawing. Aliquot store at -20C. Avoid repeated freeze / thaw cycles.
1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Protein A affinity purified.
DHP antibody; DHPDHase antibody; Dihydropyrimidine dehydrogenase [NADP(+)] antibody; Dihydropyrimidine dehydrogenase [NADP+] antibody; Dihydropyrimidine dehydrogenase antibody; Dihydrothymine dehydrogenase antibody; Dihydrouracil dehydrogenase antibody; DPD antibody; DPYD antibody; DPYD_HUMAN antibody; MGC132008 antibody; MGC70799 antibody; OTTHUMP00000058954 antibody
Belongs to the dihydropyrimidine dehydrogenase family.
Found in most tissues with greatest activity found in liver and peripheral blood mononuclear cells.
The protein encoded by this gene is a pyrimidine catabolic enzyme and the initial and rate-limiting factor in the pathway of uracil and thymidine catabolism. Mutations in this gene result in dihydropyrimidine dehydrogenase deficiency, an error in pyrimidine metabolism associated with thymine-uraciluria and an increased risk of toxicity in cancer patients receiving 5-fluorouracil chemotherapy. Two transcript variants encoding different isoforms have been found for this gene. In humans the enzyme is encoded by the DPYD gene. It is the initial and rate-limiting step in pyrimidine catabolism. It catalyzes the reduction of uracil and thymine. It is also involved in the degradation of the chemotherapeutic drugs 5-fluorouracil and tegafur. It also participates in beta-alanine metabolism and pantothenate and coa biosynthesis. The protein is a pyrimidine catabolic enzyme and the initial and rate-limiting factor in the pathway of uracil and thymidine catabolism. Genetic deficiency of this enzyme results in an error in pyrimidine metabolism associated with thymine-uraciluria and an increased risk of toxicity in cancer patients receiving 5-fluorouracil chemotherapy.